Pharmacoeconomic analysis of exemestane versus tamoxifen as adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer

被引：0
|
作者：
Gil, JM
Lluch, A
González, P
Del Castillo, A
Canorea, F
Rubio-Terrés, C
机构：
[1] Inst Catala Oncol, Barcelona, Spain
[2] Hosp Clin Univ Valencia, Valencia, Spain
[3] Pfizer, Madrid, Spain
[4] HERO Consulting, Madrid, Spain
来源：
VALUE IN HEALTH | 2005年 / 8卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)67253-1
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A37 / A38
页数：2
相关论文
共 50 条
  • [21] Adherence to endocrine therapy in patients with hormone receptor-positive early-stage breast cancer: a retrospective study
    Yan, Yi-Dan
    Fu, Jie
    Gu, Zhi-Chun
    Lu, Jin-Song
    Su, Ying-Jie
    Lin, Hou-Wen
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2023, 45 (01) : 184 - 190
  • [22] Adherence to endocrine therapy in patients with hormone receptor-positive early-stage breast cancer: a retrospective study
    Yi-Dan Yan
    Jie Fu
    Zhi-Chun Gu
    Jin-Song Lu
    Ying-Jie Su
    Hou-Wen Lin
    [J]. International Journal of Clinical Pharmacy, 2023, 45 : 184 - 190
  • [23] Personalising therapy for early-stage oestrogen receptor-positive breast cancer in older women
    Carleton, Neil
    Nasrazadani, Azadeh
    Gade, Kristine
    Beriwal, Sushil
    Barry, Parul N.
    Brufsky, Adam M.
    Bhargava, Rohit
    Berg, Wendie A.
    Zuley, Margarita L.
    van Londen, G. J.
    Marroquin, Oscar C.
    Thull, Darcy L.
    Mai, Phuong L.
    Diego, Emilia J.
    Lotze, Michael T.
    Oesterreich, Steffi
    McAuliffe, Priscilla F.
    Lee, Adrian, V
    [J]. LANCET GLOBAL HEALTH, 2022, 3 (01): : E54 - E66
  • [24] Adherence to Adjuvant Endocrine Therapy and Survival Among Older Women with Early-Stage Hormone Receptor-Positive Breast Cancer
    Park, Chanhyun
    Heo, Ji-Haeng
    Mehta, Sanica
    Han, Sola
    Spencer, Jennifer C.
    [J]. CLINICAL DRUG INVESTIGATION, 2023, 43 (03) : 167 - 176
  • [25] Adherence to Adjuvant Endocrine Therapy and Survival Among Older Women with Early-Stage Hormone Receptor-Positive Breast Cancer
    Chanhyun Park
    Ji-Haeng Heo
    Sanica Mehta
    Sola Han
    Jennifer C. Spencer
    [J]. Clinical Drug Investigation, 2023, 43 : 167 - 176
  • [26] Which Patients with Estrogen Receptor-Positive Early Breast Cancer Should Be Treated with Adjuvant Chemotherapy?
    Chiuri, Vincenzo Emanuele
    Lorusso, Vito
    [J]. ONCOLOGY, 2009, 77 : 18 - 22
  • [27] Checkpoint inhibition for early-stage hormone receptor-positive breast cancer
    Schlam, Ilana
    Corti, Chiara
    Sammons, Sarah
    Mittendorf, Elizabeth A.
    Tolaney, Sara M.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (06) : 511 - 520
  • [28] COST-EFFECTIVENESS ANALYSIS OF AROMATASE INHIBITORS AND TAMOXIFEN AS AN ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY-STAGE HORMONE RECEPTOR POSITIVE BREAST CANCER
    Sura, S. D.
    Sansgiry, S. S.
    [J]. VALUE IN HEALTH, 2012, 15 (04) : A220 - A220
  • [29] Breast Cancer Index Identifies Early-Stage Estrogen Receptor-Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence
    Zhang, Yi
    Schnabel, Catherine A.
    Schroeder, Brock E.
    Jerevall, Piiha-Lotta
    Jankowitz, Rachel C.
    Fornander, Tommy
    Stal, Olle
    Brufsky, Adam M.
    Sgroi, Dennis
    Erlander, Mark G.
    [J]. CLINICAL CANCER RESEARCH, 2013, 19 (15) : 4196 - 4205
  • [30] The choice of systemic adjuvant therapy in receptor-positive early breast cancer
    Dellapasqua, S
    Castiglione-Gertsch, M
    [J]. EUROPEAN JOURNAL OF CANCER, 2005, 41 (03) : 357 - 364
12345